Essentially, yes. Afamelanotide is the International Nonproprietary Name (INN) assigned to the pharmaceutical-grade formulation of Melanotan I. The amino acid sequence is identical; the distinction lies in formulation, manufacturing standards, and regulatory context. Scenesse – the afamelanotide 16 mg subcutaneous implant – received European Medicines Agency approval for EPP in 2014, making it one of the few melanocortin-based compounds to have completed a full regulatory pathway.

The literature reports that Melanotan I can induce measurable increases in melanin density in the absence of UV exposure, though the effect is generally more modest than when combined with low-level UV. The mechanism – MITF-driven tyrosinase upregulation – does not require UV as a co-stimulus, but UV exposure appears to amplify and accelerate the pigmentary response. Clinical trial participants have reported visible tanning in both UV-exposed and UV-unexposed skin.

Melanocytes produce two chemically distinct pigments: eumelanin (brown-black) and phaeomelanin (red-yellow). Eumelanin is the superior photoprotectant – it absorbs UV radiation across a broader spectrum and generates fewer reactive oxygen species upon UV exposure. Phaeomelanin, by contrast, may actually contribute to oxidative DNA damage under certain UV conditions. Melanotan I’s preferential induction of eumelanin synthesis is therefore not merely a cosmetic consideration; it is the mechanistic basis for the photoprotective rationale studied in EPP and PLE trials.

This is the question the field takes most seriously, and the honest answer is that the data are reassuring but not definitive. Long-term surveillance in afamelanotide-treated EPP patients has not revealed an elevated incidence of melanoma. However, MC1R is expressed on melanoma cells, and the theoretical concern – that agonism could stimulate proliferation of occult melanocytic lesions – has not been fully excluded by the available follow-up periods. Dermatological monitoring, including baseline and periodic dermoscopic evaluation of nevi, is considered standard practice in clinical trial protocols. Aeterna does not prescribe; this context is offered for educational orientation.

Afamelanotide’s EMA approval for EPP (as Scenesse) is a meaningful data point – it reflects a completed Phase III programme, a defined safety profile, and a regulatory body’s assessment of benefit-risk in a specific population. Aeterna presents this context as part of the educational record. Approval in one jurisdiction for one indication does not constitute approval elsewhere, nor does it extend to off-label applications. We do not prescribe, dispense, or sell. The monograph exists to illuminate the science so that readers can engage their own clinicians from an informed position.